Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Active | |||
Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis | Active | |||
N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Active | |||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active | |||
N/A | Nab-paclitaxel | Solid tumours | Active | |||
Velsipity | etrasimod | Ulcerative colitis | Active | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active |